<DOC>
	<DOCNO>NCT01320865</DOCNO>
	<brief_summary>The investigator hypothesize bone marrow progenitor cell mobilize circulation PAH , home lung differentiate mast cell , promote vascular remodel vasoconstriction release renin chymase . As corollary , investigator hypothesize anti cKit tyrosine kinase inhibitor ( TKI ) , nilotinib , provide clinical benefit patient inhibition mast cell progenitor proliferation , mobilization differentiation . To test , investigator determine mast cell progenitor mast cell biomarkers related nilotinib clinical response . This ancillary study , part placebo-controlled , double-blind multi center clinical trial nilotinib pulmonary arterial hypertension .</brief_summary>
	<brief_title>Biomarkers Pulmonary Arterial Hypertension Treated With Nilotinib</brief_title>
	<detailed_description />
	<criteria>This study substudy subject must enrol main trial : See Study Efficacy , Safety , Tolerability Pharmacokinetics ( PK ) Nilotinib ( AMN107 ) Pulmonary Arterial Hypertension ( PAH ) In clinical trial . ( clinical Trial ID NCT01179737 ) http : //clinicaltrials.gov/ct2/show/NCT01179737 ? Subjects enrol main study : See Study Efficacy , Safety , Tolerability Pharmacokinetics ( PK ) Nilotinib ( AMN107 ) Pulmonary Arterial Hypertension ( PAH ) In clinical trial . ( clinical Trial ID NCT01179737 ) http : //clinicaltrials.gov/ct2/show/NCT01179737 ? term=tasigna+and+pulmonary+hypertension &amp; rank=1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>